SP1 and glioblastoma: Heterozygous amplifications of ETS2 and CDK6 in TGCT; CDK6 in GBM; E2F1 and ID1 in rectum adenocarcinoma (READ); and SP1, CDK4, and MDM2 in ACC were all greater than 70% (Figure 7D).